Eledon Pharmaceuticals develops immune-modulating therapies as a clinical-stage biotechnology company focused on transplant medicine and other life-threatening conditions. Its lead investigational product, tegoprubart, is an anti-CD40L antibody designed to target the CD40 Ligand pathway, with programs and study updates tied to kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis.
Company news commonly covers tegoprubart clinical data, investigator-initiated transplant studies, FDA orphan drug designations, research collaborations, conference presentations and operating results. Updates also address how the company positions CD40L modulation as a non-lymphocyte-depleting immunomodulatory approach for preventing organ rejection and supporting transplanted cell or organ grafts.
Eledon Pharmaceuticals (NASDAQ: ELDN) will release its financial results for Q4 and the full year 2020 on March 30, 2021, after market close. A conference call and webcast will follow at 4:30 PM ET. The company, focused on developing treatments for autoimmune diseases and ALS, is advancing its lead compound, AT-1501, a targeted anti-CD40L antibody. Eledon aims to provide enhanced therapeutic solutions in immunology and transplantation.
Eledon Pharmaceuticals has appointed Jeff Bornstein, M.D. as Chief Medical Officer effective April 5, 2021, and Paul Little as Chief Financial Officer immediately. These appointments aim to strengthen the leadership team as Eledon advances its Phase 2 trial of AT-1501 for ALS and plans for additional trials. Dr. Bornstein has extensive experience in biopharmaceuticals, previously working with major companies like Takeda and Biogen, while Mr. Little brings over 30 years of finance and operations expertise from roles in Sientra and Allergan. Both executives will receive inducement grants of stock options.
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), a clinical stage biopharmaceutical company, announced that CEO David-Alexandre C. Gros, M.D. will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10. The presentation will be available on-demand starting March 9 at 7:00 am EST. Eledon focuses on developing targeted treatments for organ transplantation and immunological diseases, with its lead compound AT-1501, an anti-CD40L antibody aimed at improving immune regulation.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced that CEO David-Alexandre C. Gros, M.D. will present at the 10th annual SVB Leerink Global Healthcare Conference on February 24 at 4:20 p.m. EST. The live webcast can be accessed through Eledon's website, and a replay will be available for 90 days. Eledon focuses on developing targeted medicines for organ transplantation and immunological diseases, with its lead compound, AT-1501, targeting the CD40L pathway to potentially enhance treatment efficacy and safety.
Eledon Pharmaceuticals, a clinical-stage biopharmaceutical company focused on treatments for organ transplantation and immunological diseases, announced participation in the Noble Capital Markets' Seventeenth Annual Investor/Equity Conference. CEO David-Alexandre C. Gros will present on January 20 at 9:00 AM ET. The company is developing AT-1501, an anti-CD40L antibody aimed at improving safety and efficacy in treating autoimmune conditions and enhancing transplant success. Interested parties can access a webcast of the presentation on Eledon's website.